Please enable Javascript to use all features and improve your user experience.
EHC 2022
Programme
Posters
People
Search
EN
Posters on the topic "Migraine"
Back
P1
The TRPA1 pain pathway is a target for multiple environmental pollutants: Possible relevance for migraine
Rikke Holm Rasmussen (Glostrup/ DK)
P10
Pharmacological characterization of gepants in human and porcine vasculature
Ruben van Drie (Rotterdam/ NL)
P103
Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Krisztian Nagy (Madison, NJ/ US)
P104
A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
Robert Croop (Nerw Haven, CT/ US)
P105
Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12- and 52-Week Phase 3 Trials
Karen Carr (Chicago, IL/ US)
P106
Post-hoc Analysis Evaluating Safety of Atogepant in ADVANCE & Open-Label Extension Participants with Cardiovascular Risk Factors
Karen Carr (Chicago, IL/ US)
P107
Cut-off value for Tampa Scale for Kinesiophobia in migraine patients
Gabriella Almeida Tolentino (Ribeirão Preto/ BR)
P108
A retrospective real-life multicenter study on concurrent oral preventives in patients with chronic migraine treated with botulinum toxin
Lucas Hendrik Overeem (Berlin/ DE)
P109
Impact of Eptinezumab on Patient-Reported Outcomes in Patients With Prior Preventive Treatment Failures
Anders Ettrup (Copenhagen/ DK)
P110
Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial
Karen Carr (Chicago, IL/ US)
P111
Eptinezumab for Migraine Prevention in Patients with 2-4 Prior Treatment Failures: DELIVER Subpopulation Analysis
Patricia Pozo-Rosich (Barcelona/ ES)
P112
Efficacy and Safety of Eptinezumab for Migraine Prevention in Patients With 2–4 Prior Preventive Treatment Failures
Patricia Pozo-Rosich (Barcelona/ ES)
P113
Psychopathological disorders in chronic migraine: is there an association with the endocannabinoid system?
Sara Bottiroli (Pavia/ IT; Benevento/ IT)
P114
Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective Claims Analysis Study
Todd Schwedt (Scottsdale, AZ/ US)
P115
Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
Christopher M. Jensen (Nerw Haven, CT/ US)
P116
Adenosine causes short-lasting vasodilation and headache, but not migraine attacks in migraine patients: A randomized clinical trial
Janu Thuraiaiyah (Glostrup/ DK)
P117
Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
Krisztian Nagy (Budapest/ HU)
P118
Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: methods and global findings for diagnosis rates and care
Manjit Matharu (London/ GB)
P119
Eptinezumab Improved Work Productivity in Adults With Migraine and Prior Preventive Treatment Failures: Results From the Randomized, Double-Blind, Placebo-Controlled DELIVER Study
Anders Ettrup (Copenhagen/ DK)
P120
Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis
Karen Carr (Chicago, IL/ US)
P120a
Evaluation of PREEMPT fixed-dose, fixed-site and follow the pain treatment paradigms in the PREDICT Study
Laurent Delahaye (Rungis/ FR)
P121
The virtual "Enfacement Illusion" on pain perception in patients suffering from chronic migraine: Preliminary data from a randomized controlled trial
Sara Bottiroli (Pavia/ IT; Benevento/ IT)
P122
Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study
Susan Hutchinson (Irvine, CA/ US)
Christopher M. Jensen (Nerw Haven, CT/ US)
P123
Medication Preference, Satisfaction, and Clinical Improvement Among Adults Receiving Long-Term Treatment With Rimegepant for Migraine
Christopher M. Jensen (Nerw Haven, CT/ US)
P124
Characterizing gaps in preventive treatment of migraine: global results from the CaMEO-International study
Manjit Matharu (London/ GB)
P125
Concomitant treatment of anti-CGRP and botulinum toxin in resistant migraine, is it useful for our patients?
Candela Nieves Castellanos (Valencia/ ES)
P126
The effect or resveratrol in
ex vivo
and behavioral rat models of migraine
Philip Reducha (Copenhagen/ DK)
P127
Is migraine causally linked to inflammatory bowel disease or coeliac disease? A Mendelian randomisation study
Nike Welander (Uppsala/ SE)
P128
Medication overuse and patient-reported outcome of
OnabotulinumtoxinA
treatment in Chronic Migraine
Catarina Fernandes (Coimbra/ PT)
P129
Atogepant for the Preventive Treatment of Chronic Migraine in Europe: Results From the PROGRESS Study
Peter J. Goadsby (Los Angeles, CA/ US; London/ GB)
P130
Additional effects of pain neuroscience education combined with physiotherapy on the headache frequency of adult patients with migraine – a randomized controlled trial
Ruth Meise (Luebeck/ DE)
P131
Assessing Hypersensitivity, Cortical Hyperexcitability, and Habituation in Migraine, according to Age and Disease Severity, using Visual Evoked Potentials during Pattern-Reversal Stimulation
Angela Marti-Marca (Barcelona/ ES)
P132
Effects of vitamin B1, B6, and B12 on serum levels of CGRP, endothelial nitric-oxide synthase, homocysteine, and headache characteristics in women with episodic migraine
Shiva Nematgorgani (Tehran/ IR)
P133
Quantifying aversion thresholds to light, sound, smell, and touch in migraine: A longitudinal study in migraine and non-headache controls
Nara Ikumi (Barcelona/ ES)
P134
Negative impact of under-diagnosed migraine in university students in Slovakia
Oľga Duraníková (Bratislava/ SK)
Simona Horváthová (Bratislava/ SK)
P135
Change in Migraine Diagnosis After Preventive Treatment With Eptinezumab: Post Hoc Analysis of the PROMISE Studies
Patricia Pozo-Rosich (Barcelona/ ES)
P136
Hormonal treatment for menstrual migraine: rationale and protocol of the WHAT!-Trial
Britt van der Arend (Leiden/ NL; Rotterdam/ NL)
P136a
Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
Robert Croop (Nerw Haven, CT/ US)
P137
Identification of crystal-clear days in migraine using data of a nation-wide population-based study
Wonwoo Lee (Yongin/ KR; Seoul/ KR)
P137a
Long-Term Treatment With Lasmiditan in Patients With Migraine: Results From the Open-Label Extension of the CENTURION Study
Saygin Gonderten (Dubai/ AE)
P138
Patterns of use of monoclonal antibodies for the preventive treatment of migraine: Results from the OVERCOME (EU) study
Stefan Evers (Münster/ DE)
Saygin Gonderten (Dubai/ AE)
P139
Cardiovascular risk factors and migraine: Results from the population-based Rotterdam study
Linda Al-Hassany (Rotterdam/ NL)
P140
A prospective evaluation of neurological presentations to a National Neuro-Behçet Clinic in the UK- Migraine is the commonest neurological complaint in Behçet's disease
Mona Ghadiri-Sani (Liverpool/ GB)
P141
Safety and tolerability of atogepant: a post hoc analysis of pooled data from four clinical trials
Krisztian Nagy (Budapest/ HU)
P142
Effect of atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Krisztian Nagy (Budapest/ HU)
P143
Effect of atogepant on the Activity Impairment in Migraine–Diary and Work Productivity and Activity Impairment Questionnaire in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Richard B. Lipton (Bronx, NY/ US)
P144
Erenumab as a first line preventive treatment for episodic migraine in Spain: a cost-effectiveness analysis.
Pablo Irimia (Pamplona/ ES)
P145
Impact of migraine attack accompanying symptoms in treatment response to anti-CGRP monoclonal antibodies treatment and their evolution after 6 months
Alicia Alpuente (Barcelona/ ES)
P146
Mapping Migraine Minds: A cross-sectional survey to compare the difference in the level of treatment expectations and satisfaction for migraine among Indian male & female patients
Sneha Thakur (Mumbai/ IN)
P147
Migraine, chronic neck pain and endurance muscle cervical test – a controlled study
Amanda Rodrigues (Ribeirão Preto/ BR)
P148
Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study
Christopher M. Jensen (Nerw Haven, CT/ US)
P149
Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
Christopher M. Jensen (Nerw Haven, CT/ US)
P150
Onabotulinum toxinA for unremitting chronic migraine: assessment of muscle function and strength, efficacy and safety after 10 years of continuous treatment.
Guy Pierre Boudreau (Montreal/ CA)
P151
Long-term Effectiveness and Safety of Erenumab in patients with Migraine: a Systematic Review and Single-Arm Meta-analysis
Fernanda Ferreira Bomtempo (Belo Horizonte/ BR)
P152
Prospective evaluation of migraine premonitory symptoms during the 30 days period
Kirill Skorobogatykh (Moscow/ RU)
P153
Prevalence of sinonasal symptoms in migraine without aura (results from
Migraine in Poland -
a nationwide cross-sectional survey)
Marcin Straburzyński (Olsztyn/ PL)
P154
Evaluation of a mandatory drug holiday during treatment with monoclonal antibodies targeting the cgrp pathway: a patient survey
Jan Versijpt (Brussel/ BE)
P155
Use of CGRP monoclonal antibodies and patient-reported improvement: Results from the OVERCOME (EU) study
Stefan Evers (Münster/ DE)
Saygin Gonderten (Dubai/ AE)
P156
Total tau concentrations are increased in blood serum of migraine patients: A cross-sectional case-control study
Lucas Hendrik Overeem (Berlin/ DE)
P157
Disconnectome of the Migraine Brain: A Model of Migraine as "Connectopathy"
Antonio Russo (Naples/ IT)
P158
Changes in Sensitization and Habituation Measured by Algometry in Chronic Migraine Patients Treated with Onabotulinumtoxin A
Ángel Luis Guerrero Peral (Valladolid/ ES)
P159
Mapping Migraine Minds: A cross-sectional survey to compare the difference in burden of migraine among Indian male & female patients
Sneha Thakur (Mumbai/ IN)
P160
Whole-brain functional connectome alterations in patients with migraine
Chae Hyeon Lee (Incheon/ KR)
P161
Interictal IgE and tryptase levels in episodic and chronic migraine
Min Kyung Chu (Seoul/ KR)
P162
Efficacy and safety of once monthly subcutaneous erenumab 70 mg in adult chronic migraine patients (primary analysis): Indian sub analysis from Global DRAGON study
Sneha Thakur (Mumbai/ IN)
P163
Subjective Tinnitus in Pediatric and Adolescent Migraine Versus Other Primary Headaches – a Prospective, Comparative Study
Tal Eidlitz Markus (Tel Aviv/ IL; Petach Tikva/ IL)
P164
Influence of Neck Pain in Response to Cervical Spine Manual Palpation on Neck Proprioception and Muscle Endurance of Migraine Patients and Controls
Gabriela F Carvalho (Luebeck/ DE)
P165
Association Between Migraine and Transient Global Amnesia: An Inpatient Sample Analysis
Christian Lampl (Linz/ AT)
P166
Gradually shifting clinical phenomics in migraine spectrum: A Cross-sectional, Multicenter study of 5438 patients
Ye Ran (Beijing/ CN)
P167
Characterization of the spectral content of resting-state electroencephalographic activity in chronic migraine female patients
Víctor Gutiérrez-de Pablo (Valladolid/ ES)
P168
Impact of air pollution exposure on headache onset in migraine patients
Alicia Alpuente (Barcelona/ ES)
P169
A Cohort Study Comparing Melatonin-users with Non-users in the treatment of Migraine Headaches.
Shreyans Singhvi (Jodhpur/ IN)
P170
Epilepsy in Migraine Aggravates the Cognitive Disorders
Maruf Mavlanov (Tashkent/ UZ)
P171
Impact of migraine in Indian housewives: A subset analysis from Mapping Migraine Minds study- A cross-sectional study to compare the difference in burden of migraine among Indian males & females
Sneha Thakur (Mumbai/ IN)
P172
The effect of botulinum toxin on anxiety and depression scales in chronic and high frequency migraneurs
Joana Moniz Dionísio (Lisbon/ PT)
P173
Intravenous lidocaine and ketamine infusions for headache disorders: a retrospective cohort study
Jason Ray (Melbourne/ AU)
P174
HEADWORK as innovative tool for monitoring MABs efficacy in migraine and their influence on work activity.
Gloria Vaghi (Pavia/ IT)
Licia Grazzi (Milano/ IT)
P175
Optimization of Acute Treatment in Migraine Patients Treated with Monoclonal Antibodies Acting on the CGRP Pathway
Chiara Rosignoli (L'Aquila/ IT)
P176
Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Real World Data from two Prospective Studies using a Digital Therapeutic
Torsten Schroeder (Luebeck/ DE)
P177
Iprazochrome and codeine – unlikely winners in migraine treatment in Poland. Targeting areas for improvement in migraine treatment (results from
Migraine in Poland
- a nationwide cross-sectional survey)
Marta Waliszewska-Prosół (Wroclaw/ PL)
P178
Alternative Indirect Treatment Comparisons for Eptinezumab in Migraine Prevention
Xin Ying Lee (Copenhagen/ DK)
P179
Clinical pattern and response to treatment of predominant posterior migraine
Gonçalo Cabral (Lisbon/ PT)
P180
Classification of the pain curve and semiology of a migraine crisis
Alicia Gonzalez-Martinez (Madrid/ ES)
P181
Evolution of practice guidelines for the treatment of acute migraine with Paracetamol (Acetaminophen)
Michel Lanteri-Minet (Nice/ FR)
P182
Craniocervical Flexion Test in patients with migraine: discriminatory validity and accuracy
Amanda Rodrigues (Ribeirão Preto/ BR)
P183
Prevalence, disease profile, treatment patterns and burden of migraine in India: An internet-based survey
Debashish Chowdhury (Delhi/ IN)
P184
Use of Carbamazepine in Patients with Migraine-Comorbid Epilepsy in The Uzbek Population
Maruf Mavlanov (Tashkent/ UZ)
P186
Treatment of Migraine in children and adolescents
Jacob Genizi (Haifa/ IL)
P187
Vitamins and migraine? Is it a matter? The possible effects and suggested pathophysiology
Mansoureh Togha (Tehran/ IR)
P188
Vestibular Migraine: Management differences between General Neurology and Neuro-Otology
Maria Dolores Villar-Martinez (London/ GB)
P190
Prediction of a migraine crisis in real-time using a wearable device
Alicia Gonzalez-Martinez (Madrid/ ES)
P191
Utility of machine-learning based models to predict 30%, 50% and 75% response to anti-CGRP response in patients with migraine: a multicenter Spanish study
Alicia Gonzalez-Martinez (Madrid/ ES)
P195
Machine prescription for chronic migraine
Erling Tronvik (Trondheim/ NO)
P198
@TrialMigraine: A Daily Migraine Clinical Trials Tracker
Pengfei Zhang (New Brunswick, NJ/ US; Dayton, NJ/ US)
P2
Functional responses in a patient-specific iPSC-derived vascular model: a novel approach to study migraine
Tessa de Vries (Rotterdam/ NL)
P201
The structure and organization of headache differential diagnoses: A Pilot Study of Subset Relationships between Differentials in ICHD3
Pengfei Zhang (New Brunswick, NJ/ US)
P202
A comprehensive list of prevention medications without drug-drug interactions can be generated from DrugBank and FAERS
Pengfei Zhang (New Brunswick, NJ/ US)
P206
How to sequentially try all possible "pick two" combinations of abortive and/or prevention medications: an exploration in hamiltonian cycles in headache
Pengfei Zhang (New Brunswick, NJ/ US; Dayton, NJ/ US)
P217
Idiopathic intracranial hypertension presenting with migraine phenotype is associated with unfavorable headache outcome
Gabriel Bsteh (Vienna/ AT)
P227
Sleep Disorders in Pediatric Migraine: a questionnaire-based study
Alessandra Voci (Rome/ IT)
P23
Coexistence of migraine and cluster headache - is it more than just a coincidence?
Jelena Gulišija (Split/ HR)
P230
Cutaneous allodynia in pediatric and adolescent patients and their mothers – a comparative study
Tal Eidlitz Markus (Tel Aviv/ IL; Petach Tikva/ IL)
P232
Long-term effects of pandemic of Covid-19 on clinical features and psychological symptoms in adolescents with migraine
Martina Proietti Checchi (Rome/ IT)
Samuela Tarantino (Rome/ IT)
P234
The influence of anxiety and depression on headache in adolescent migraineurs: A case-control study
Elham Jafari (Tehran/ IR)
P235
Abnormal eye movements in a girl with Vestibular migraine: a case report and review of the literature
Fatemeh Farham (Tehran/ IR)
P236
Allodynia and muscle sensitization of cervical muscles are not associated with neck range of motion in children and adolescents diagnosed with migraine
Juliana Pradela (Ribeirão Preto/ BR)
P238
Does symptomatic treatment help children and adolescents with chronic migraine?
Michela Ada Noris Ferilli (Rome/ IT)
P239
Angelman syndrome and cyclic vomiting syndrome: a new potential association –
Not all the vomiting are only vomiting!
Giorgia Sforza (Rome/ IT)
Giacomo Racioppi (Rome/ IT)
P240
Clinical characteristics of children and adolescents with primary and secondary headaches in the tertiary-level of a public hospital in Brazil
Juliana Pradela (Ribeirão Preto/ BR)
P241
Sars-Cov-2 and Headache in Children and adolescents
Nana Kapanadze (Tbilisi/ GE)
P242
Prevalence of neck pain in migraine: A systematic review and meta-analysis
Haidar Muhsen Al-Khazali (Glostrup/ DK)
P245
Characterizing opioid use in a Dutch cohort with migraine
Rein van Welie (Leiden/ NL)
P246
The association of innate and adaptive immunity with migraine in The Rotterdam Study: a population-based cohort study
Cevdet Acarsoy (Rotterdam/ NL)
P249
Visual aura in non-migrainous headache: a population study
Min Kyung Chu (Seoul/ KR)
P256
Migraine Should Be First Focus on Headache Education in the Middle East, Asia, and Africa: A subgroup analysis of the Head-MENAA Study
Hamit Genç (Van/ TR)
P257
Switching from anti-CGRP-receptor mAb (erenumab) to an anti-CGRP-molecule mAbs (fremanezumab) in chronic migraine: results of a real-world study
Valeria Caponnetto (London/ GB; L'Aquila/ IT)
P258
REAL-WORLD FREMANEZUMAB EXPERIENCE FROM HEADACHE CLINIC IN MOSCOW
Alikhan Uzhakhov (Moscow/ RU)
P259
Discontinuation after one-year of treatment with anti-CGRP antibodies did not provide long-term sustained response without therapy
Luigi Francesco Iannone (Florence/ IT)
P260
Anti-CGRP monoclonal antibodies and peripheral sensitization: a study on Pressure Pain Threshold in migraineurs
Gabriele Garascia (Trieste/ IT)
P262
Is it worth switching monoclonal antibodies?
Elsa Parreira (Amadora/ PT)
P263
Study on the presence of comorbidities in a series of 200 patients with migraine and their influence on the effectiveness of fremanezumab.
Noemí Morollón Sánchez-Mateo (Barcelona/ ES)
P264
Predictors of galcanezumab response in Korean patients with migraine
Miji Lee (Seoul/ KR)
P265
Can We Descriminate Migraine Susceptibile to CGRP Antagonism?
Marjan Zaletel (Grosuplje/ SI)
P266
Interim Analysis on the Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: The Observational PEARL Study
Messoud Ashina (Copenhagen/ DK)
P267
Response patterns in migraine patients in prophylactic treatment with different anti-CGRP pharmacological blockade systems
Francesca Schiano di Cola (Brescia/ IT)
P268
Effect of Galcanezumab in Migraine and Concomitant Medication Overuse Headache Without Prior Drug Withdrawal
Javier A. Membrilla (Madrid/ ES)
P269
Factors associated with favorable outcome in galcanezumab treatment for chronic migraine: A clinic-based prospective study
Byung-kun Kim (Seoul/ KR)
P270
Past Preventive Migraine Treatment in Patients Initiating Fremanezumab in Clinical Practice: Interim Data from the PEARL Study
Messoud Ashina (Copenhagen/ DK)
P272
Descriptive study on the presence, treatment and evolution of comorbidities in a series of 200 migraine patients treated with fremanezumab.
Noemí Morollón Sánchez-Mateo (Barcelona/ ES)
P273
Response to fremanezumab in migraine patients with and without prior aCGRP mAbs - preliminary data from the FINESSE study
Charly Gaul (Frankfurt a.M./ DE)
P274
Could Symptom Severity Predict the Response to Anti-Cgrp Monoclonal Antibodies in Migraine?
Javier A. Membrilla (Madrid/ ES)
P276
Prevalence of migraine according to Migraine Screening-Questionnaire (MS-Q) and headache characteristics in patients with inflammatory bowel disease (IBD)
Alicia Gonzalez-Martinez (Madrid/ ES)
P277
Influence of migraine and migraine aura on the prescription of hormonal contraception in German outpatient gynecological clinics
Mira Fitzek (Berlin/ DE)
P278
Sex differences in migraine attack characteristics: a longitudinal E-diary study
Iris Verhagen (Leiden/ NL; Rotterdam/ NL)
P279
Ketogenic diet for migraine prevention: an effective option beyond weight loss
Mariarosaria Valente (Udine/ IT)
P29
Impact of migraine on the presentation of reversible cerebral vasoconstriction syndrome
Kristin Sophie Lange (Berlin/ DE; Montpellier/ FR)
P3
Relevance of mouse vasculature in investigating side-effects of anti-migraine medications.
Spyridoula Kazantzi (Copenhagen/ DK)
P38
Characterization of adult patients with status migrainosus in a tertiary hospital in Colombia, 2019-2021
Reydmar Lopez-Gonzalez (Medellin/ CO)
P39
Implementing a digital treatment solution for headache patients – a pilot study.
Triinu Niiberg-Pikksööt (Tartu/ EE; Tallinn/ EE)
P4
Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental chronic migraine rat model
Yixin Zhang (Chongqing/ CN)
P40
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine
Song Guo (Copenhagen/ DK)
P42
Prevalence of temporomandibular disorders with comorbid migraine: A retrospective study in a 5-year period
Pankaew Yakkaphan (LONDON/ GB)
P47
Neurovascular Orofacial Pain – A Diagnostic Dilemma
Sumit Gupta (Ras Al Khaimah/ AE)
P5
An open-source electrophysiology system to explore visual evoked potentials in migraine
Hui Zhou Chen (London/ GB)
P50
Real-world Reductions in Monthly Migraine Days and Migraine-Related Healthcare Resource Utilization in UK Patients Using Fremanezumab
Hasan Akcicek (Amsterdam/ NL)
P51
Anti-CGRP mAbs in a difficult to treat migraine population. Efficacy and safety.
Diaz Insa Samuel (Valencia/ ES)
P52
The efficacy of CGRP monoclonal antibodies – an Australian experience
Jason Ray (Melbourne/ AU)
P53
Use of non-pharmacological therapies in individuals with migraine eligible for treatment with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP)-signaling: a single-center cross-sectional observational study
Christopher Kjaer Cullum (Glostrup/ DK)
P54
Role of Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide or Receptor (CGRP-Mabs) for Chronic Migraine Prevention: A Critical Review
Samiran Chowdhury (Lucknow/ IN)
P55
Real Life Experience: Use of CGRP Inhibitors in Patients Older than 55 Years Old, are they Safe and Effective?
Maria Victoria Castro Sanchez (Malaga/ ES)
P56
Real life experience and learning curve of Galcanezumab in migraine. Galca-only Consortium
Victor Obach (Barcelona/ ES)
P59
Investigating the Long-Term Efficacy of Calcitonin Gene Related Peptide Monoclonal Antibodies
Amira Salim (Cleveland/ US)
P6
Effects of caffeine on intracranial pressure and pain perception in freely moving rats
Sajedeh Eftekhari (Glostrup/ DK)
P61
Diagnostic utility of T2*-weighted GRE in migraine with aura attack. The cortical veins sign
Chloé Hirtz (Marseille/ FR)
P62
Emotional processing differences between migraine and tension-type headache subjects – an fMRI study
Dora Dobos (Budapest/ HU)
P63
Dynamic functional connectivity in migraine during the interictal phase: a resting-state fMRI study
Inês Esteves (Lisbon/ PT)
P64
Reliable posterior insula–operculum region gray matter volume alterations in vestibular migraine
Liang Dong (Chongqing/ CN)
Jiying Zhou (Chongqing/ CN)
P67
White-matter microstructural changes in episodic menstrual migraine compared with
hormonal controls
Ana Fouto (Lisbon/ PT)
P68
Neuroimaging Utilization in Telemedicine Relative to In-Person Initial Visits for Migraine and Headache at a Tertiary Headache Center: A One-Year Analysis
Bradley Torphy (Chicago/ US)
P73
Clinical manifestations and impact of SARS-CoV-2 infections and vaccines in patients with migraine
Edoardo Caronna (Barcelona/ ES)
P77
Effect of Covid 19 Infection on Episodic Migraine Patients in Saudi Populations and Role of Vaccination
Hossam Younis (Jeddah/ SA)
Mostafa Meshref (Cairo/ EG; Riyadh/ SA)
P91
Glibenclamide posttreatment does not inhibit levcromakalim induced headache: A randomized clinical trial
Lili Kokoti (Glostrup/ DK)
P93
Recording pre-ictal migraine changes in cortical responsivity using EEG in a patient's home environment
Thomas van den Hoek (Leiden/ NL)
P94
Vestibular signs in experimentally induced migraine attacks: a post-hoc, exploratory analysis
Michele Corrado (Pavia/ IT)
v1.21.0
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy